BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20336161)

  • 1. Pituitary gland: can prolactinomas be cured medically?
    Molitch ME
    Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
    Miki N
    Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
    Pereira AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
    McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
    Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
    J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
    Kharlip J; Salvatori R; Yenokyan G; Wand GS
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
    Sosa-Eroza E; Espinosa-Cárdenas E
    Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Delgrange E; Donckier J
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactinomas.
    Couldwell WT; Weiss MH; Laws ER
    N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 15002121
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabergoline and quinagolide therapy for prolactinomas.
    Webster J
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):549-50. PubMed ID: 11106914
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?
    Klibanski A
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2247-9. PubMed ID: 19584197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.